A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

• Status: Completed
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Academic Myeloma Consortium; Criterium, Inc.
• Collaborators: Amgen; Celgene Corporation; Criterium, Inc.; Onyx Pharmaceuticals
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Pomalidomide; Thalidomide

Criteria

Inclusion Criteria:

• Cytopathologically or histologically confirmed dx of multiple myeloma

• Relapsed or refractory to the most recently received therapy.

• All pts must have received prior lenalidomide therapy and been determined to be refractory, relapsed, or intolerant.

• Measurable disease, as indicated by one or more of the following:

Serum M-protein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain as per IMWG criteria, and abnormal ratio

• Pts must be ≥ 18 years of age

• Life expectancy of more than 3 months

• ECOG PS of 0-2

• Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN

• Uric acid must be within laboratory normal range

• CrCl ≥ 50 mL/min

• Additional Laboratory Requirements ANC ≥1.0 x 109/L Hgb ≥8 g/dL(transfusion permitted) Platelet count ≥50.0 x 109/L

• Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks

• Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines

• Screening platelet count should be independent of platelet transfusions for at least 2 weeks.

• Written informed consent in accordance with federal, local, and institutional guidelines

• FCBP must agree to ongoing pregnancy testing

• FCBP must have a negative serum or urine pregnancy test and agree to birth control.

• Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.

• Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study.

• All pts must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

• Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion

Exclusion Criteria:

• Pts with known sensitivity to any immunomodulatory drugs (IMiDs)

• Use of any other experimental drug or therapy within 21 days prior to first dose

• Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within 14 days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period.

• Radiation therapy within 14 days prior to first dose

• Known allergies to carfilzomib or Captisol

• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

• Current diagnosis of plasma cell leukemia

• Waldenström's macroglobulinemia

• Major surgery within 21 days prior to first dose

• Pregnant or lactating females

• Congestive heart failure (NYHA class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months prior to first dose.

• Uncontrolled hypertension

• Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose

• Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.

• Serious psychiatric or medical conditions that could interfere with treatment

• Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment

• Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparin

• Pts in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment

• Pts with primary systemic amyloidosis

• Pts who have received prior treatment with carfilzomib (Phase II only)

• Pts who have received prior treatment with pomalidomide (Phase II only)

• Pts who have received prior treatment with both carfilzomib & pomalidomide (Phase I only)